Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Affiliations

¹ Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
² National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
³ Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health, Bethesda, MD, USA.
⁴ Magnetoencephalography Core Facility, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
⁵ Departments of Psychiatry, Pharmacology, and Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
⁶ Veterans Affairs Maryland Health Care System, Baltimore, MD, USA.
⁷ Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. zaratec@mail.nih.gov.

Published Erratum

Cristan A Farmer et al. Neuropsychopharmacology. 2020 Jul.

. 2020 Jul;45(8):1405.

doi: 10.1038/s41386-020-0699-7.

¹ Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
² National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
³ Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health, Bethesda, MD, USA.
⁴ Magnetoencephalography Core Facility, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.
⁵ Departments of Psychiatry, Pharmacology, and Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA.
⁶ Veterans Affairs Maryland Health Care System, Baltimore, MD, USA.
⁷ Section on the Neurobiology and Treatment of Mood Disorders, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA. zaratec@mail.nih.gov.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.
Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, Nugent AC, Kadriu B, Yuan P, Gould TD, Park LT, Zarate CA Jr. Farmer CA, et al. Neuropsychopharmacology. 2020 Jul;45(8):1398-1404. doi: 10.1038/s41386-020-0663-6. Epub 2020 Apr 6. Neuropsychopharmacology. 2020. PMID: 32252062 Free PMC article. Clinical Trial.